• Brii Bio published 2025 annual report, highlighting progress in hepatitis B functional cure program built around BRII-179 and elebsiran.
• Phase 2b ENSURE, ENRICH, ENHANCE studies completed enrollment; confirmatory ENRICH and ENHANCE readouts expected in second half of 2026.
• ENSURE Cohort 4 results presented at 2025 AASLD meeting, published in Nature Medicine; data supported BRII-179 role in improving HBsAg loss outcomes.
• ENHANCE protocol amended in 2025 to test alternative triple regimen designed to cut PEG-IFNα duration to 24 weeks.
• Non-core portfolio reshaped via July 2025 Greater China out-license of soralimixin to Joincare Group; HIV asset partnering remained under evaluation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260423-12117633), on April 23, 2026, and is solely responsible for the information contained therein.